Targeted cisplatin infusion for children with diffuse midline glioma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new way to deliver a drug called cisplatin directly to a type of brain tumor called diffuse midline glioma (including DIPG) after radiation. The goal is to see if this targeted approach can improve outcomes for children and young adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 21 years old.
- You must have a type of brain tumor called diffuse midline glioma (including DIPG).
- You must have already completed radiation therapy, and it should have started within 6 weeks of your diagnosis.
- You must be between 4 and 12 weeks after finishing radiation, and have had an MRI after radiation.
- You must be generally healthy – able to do daily activities and without major heart, kidney, liver, or blood problems.
- You cannot be taking blood thinners, certain other medications, or have active infections or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
This trial tests if combining focused ultrasound (which opens the blood-brain barrier) with the immunotherapy drug nivolumab can treat relapsed or progressive brainstem gliomas and other high-grade brain tumors in children and young adults.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial tests a combination of three drugs (temozolomide, anlotinib, and bemarituzumab) along with radiation therapy for children with a type of brain tumor called diffuse midline glioma. The goal is to see if this approach can help shrink or control the tumor when surgery cannot remove it completely.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This trial tests injecting cisplatin directly into lung or lymph node tumors for people with stage IV non-small cell lung cancer. It aims to see if this approach is safe and could help control the cancer.
Hear when a new Diffuse Midline Glioma (DMG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.